Gland Pharma balance sheet

As of Mar 2026

Total assets: ₹12,511cr+11.5% on Mar 2025
Shareholders' equity: ₹10,358cr+13.2% on Mar 2025
Total debt: ₹243cr−9.6% on Mar 2025
Cash and investments: ₹3,359cr+31.4% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	4,052	3,751	3,541	1,559
	342	151	238	177
	294	248	242	0.0
	109	106	112	11.7
	125	0.0	656	0.0
	125	0.0	656	0.0
	62.3	52.1	50.4	0.0
	—	135	176	129
	4,984	4,442	5,016	1,877
	1,744	1,685	1,655	1,945
	1,891	1,517	1,559	871
	3,359	2,556	357	1,909
	0.0	0.0	1,482	1,862
	0.0	0.0	0.0	0.1
	73.7	494	252	65.5
	5,324	4,566	3,650	4,708
	459	531	340	248
	7,527	6,783	5,645	6,901
	12,511	11,225	10,661	8,778
Equity
	16.5	16.5	16.5	16.5
	10,341	9,134	8,707	7,942
	10,358	9,151	8,724	7,959
	10,358	9,151	8,724	7,959
Liabilities
	69.9	77.7	107	3.3
	23.3	29.5	34.7	2.2
	93.2	107	141	5.5
	196	146	137	0.0
	214	215	220	84.2
	41.2	41.4	40.5	0.0
	544	509	539	89.7
	173	192	213	0.6
	834	820	863	587
	166	126	27.0	16.5
	1,173	1,138	1,103	604
	54.1	50.9	58.9	31.3
	62.9	73.7	51.6	1.0
	318	302	185	92.5
	1,608	1,565	1,398	729
	2,153	2,074	1,937	819
	12,511	11,225	10,661	8,778
Trade payables — MSME split
	834	820	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLAND₹3,074.50

Gland Pharma Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB AUROPHARMA PPLPHARMA SYNGENE WOCKPHARMA ASTERDM COHANCE LALPATHLABMcap ₹50,655 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	1,558.5	3,541.3	3,750.5	4,052.0	4,052.0
+ Capital Work-in-Progress	177.2	237.9	150.6	342.2	342.2
+ Goodwill	0.0	242.3	248.2	293.9	293.9
+ Other Intangibles	11.7	112.2	105.7	108.6	108.6
+ Other Non-current Financial Assets	0.0	655.9	0.0	125.1	125.1
Non-current Financial Assets	0.0	655.9	0.0	125.1	125.1
+ Deferred Tax Assets	0.0	50.4	52.1	62.3	62.3
+ Other Non-current Assets	129.3	176.1	134.9	—	—
Total Non-current Assets	1,876.7	5,016.1	4,442.0	4,984.1	4,984.1
Current Assets
+ Inventories	1,945.3	1,655.2	1,685.2	1,743.9	1,743.9
+ Trade Receivables	871.4	1,558.7	1,516.5	1,891.4	1,891.4
+ Cash & Cash Equivalents	1,908.9	357.1	2,556.2	3,359.1	3,359.1
+ Other Bank Balances	1,861.8	1,482.3	0.0	0.0	0.0
+ Short-term Loans	0.1	0.0	0.0	0.0	0.0
+ Other Current Financial Assets	65.5	251.9	493.6	73.7	73.7
Current Financial Assets	4,707.7	3,650.1	4,566.4	5,324.2	5,324.2
+ Other Current Assets	247.8	339.9	531.4	458.7	458.7
Total Current Assets	6,900.8	5,645.2	6,782.9	7,526.8	7,526.8
Total Assets	8,777.5	10,661.2	11,224.9	12,510.8	12,510.8
Equity
+ Equity Share Capital	16.5	16.5	16.5	16.5	16.5
+ Other Equity / Reserves	7,942.3	8,707.4	9,134.3	10,341.5	10,341.5
Equity — Owners of Parent	7,958.7	8,723.8	9,150.7	10,358.0	10,358.0
Total Equity	7,958.7	8,723.8	9,150.7	10,358.0	10,358.0
Liabilities
+ Borrowings — Non-current	3.3	106.5	77.7	69.9	69.9
+ Other Non-current Financial Liab	2.2	34.7	29.5	23.3	23.3
Non-current Financial Liabilities	5.5	141.2	107.2	93.2	93.2
+ Provisions — Non-current	0.0	137.2	146.0	195.6	195.6
+ Deferred Tax Liabilities	84.2	220.1	214.8	214.4	214.4
+ Other Non-current Liabilities	0.0	40.5	41.4	41.2	41.2
Non-current Liabilities	89.7	539.0	509.3	544.5	544.5
+ Borrowings — Current	0.6	213.2	191.6	173.4	173.4
+ Trade Payables	587.4	862.7	820.4	833.9	833.9
+ Other Current Financial Liab	16.5	27.0	126.1	165.6	165.6
Current Financial Liabilities	604.4	1,102.9	1,138.0	1,172.9	1,172.9
+ Provisions — Current	31.3	58.9	50.9	54.1	54.1
+ Current Tax Liabilities	1.0	51.6	73.7	62.9	62.9
+ Other Current Liabilities	92.5	184.9	302.3	318.5	318.5
Current Liabilities	729.1	1,398.4	1,564.8	1,608.4	1,608.4
Total Liabilities	818.8	1,937.4	2,074.2	2,152.9	2,152.9
Total Equity & Liabilities	8,777.5	10,661.2	11,224.9	12,510.8	12,510.8
Trade Payables — MSME split
+ Dues to Other Creditors — Current	—	—	820.4	833.9	833.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.